Document is current
Any future updates will be listed below
-
Authors
Rosen, David B https://orcid.org/0000-0002-9856-7675
Kvarnhammar, Anne Månsson
Laufer, Burkhardt
Knappe, Thomas
Karlsson, Jens Jakob
Hong, Enping
Lee, Yu-Chi
Thakar, Dhruv
Zúñiga, Luis Alejandro https://orcid.org/0000-0002-1832-122X
Bang, Kathy
Sabharwal, Simran Singh
Uppal, Karan
Olling, Janne Damm
Kjaergaard, Kristian
Kurpiers, Thomas
Schnabel, Meike
Reich, Diana
Glock, Philipp
Zettler, Joachim
Krusch, Mathias
Bernhard, Ana
Heinig, Stefan
Konjik, Valentino
Wegge, Thomas
Hehn, Yvonne
Killian, Steffen
Viet, Laura
Runz, Josefine
Faltinger, Frank
Tabrizi, Mohammad
Abel, Kristin Laura
Breinholt, Vibeke Miller
Singel, Stina M
Sprogøe, Kennett
Punnonen, Juha
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05081609 at ClinicalTrials.govnct05081609 at ClinicalTrials.govDocuments that mention this clinical trial
TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2601
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
https://doi.org/10.1136/jitc-2022-004991
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14597
Documents that mention this clinical trial
TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2601
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
https://doi.org/10.1136/jitc-2022-004991
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14597
-
Funding
Funding for this research was provided by:
Ascendis Pharma
- License Information
